Wegovy 1mg 0.5ml: understanding this dose step in the titration sequence

Step 1: how you arrive at 1mg in the titration sequence

The Wegovy titration schedule exists for one practical reason: your digestive system needs time to adjust to a GLP-1 receptor agonist. Semaglutide slows gastric emptying and changes how hunger signals reach the brain, useful effects, but ones the gut needs to meet gradually. The licensed UK pathway starts at 0.25mg for four weeks, then moves to the 0.5mg step, which you can read about in detail on our wegovy 0.5 ml page for a further four weeks, and then to the 1mg dose you are reading about now.

At 1mg, most people are past the steepest part of the adjustment curve. The nausea and queasiness that can accompany earlier dose increases often settle more quickly at this level than they did at the start, though that varies person to person, and your prescriber is the right person to talk to if they don't. The pen itself delivers 1mg of semaglutide in a 0.5ml injection, once weekly, into the abdomen, thigh or upper arm, rotating the site each time. More detail on this dose level covers what clinical evidence shows at the 1mg mark specifically.

One thing worth clearing up: some people assume the 1mg step is where treatment starts to work and earlier doses were wasted. That's not quite right. The 0.25mg and 0.5mg steps are doing real physiological work, just at a level designed to protect tolerability. The cumulative adjustment is the point.

Step 2: what the 1mg dose does (and doesn't) mean for your progress

The 1mg/0.5ml pen sits in the middle of the titration ladder, and it is honest to say that many people haven't yet reached their full therapeutic response at this stage. The large STEP 1 trial, published in the New England Journal of Medicine, reported an average body-weight reduction of around 15% at 68 weeks on semaglutide 2.4mg, that headline figure reflects the full maintenance dose, reached after months of structured titration. The 1mg step is a waypoint, not the destination.

That said, appetite reduction is often clearly noticeable by the time people reach 1mg. Smaller portion sizes, less urgency around food, and greater fullness from meals are commonly reported. These are signs the medicine is working as intended, even before the higher doses are reached. Tracking progress at this stage is useful not as a scorecard but as information for your prescriber, they need to know how you are tolerating the step before deciding whether to move you on. If you are unsure where to learn more about how Wegovy works across its full course, that page covers the broader picture.

Storage at this stage follows the same rule as every other Wegovy pen: refrigerate between 2 and 8°C, and consult the Patient Information Leaflet supplied with your pen for the precise details on any room-temperature window, those instructions are specific to the product and the leaflet is the authoritative source.

Step 3: side effects to expect, and when to get medical help

At the 1mg level, the side-effect profile is broadly similar to earlier steps but may feel more noticeable simply because the dose is higher. The most commonly reported effects are gastrointestinal: nausea, loose stools, constipation, reflux, or a general sense of digestive sluggishness. Fatigue and mild headache are also reported. The NHS medicines page for semaglutide lists these clearly and is worth bookmarking for reference.

Most GI effects at a new dose step peak in the first week or two and then settle. Eating smaller meals, avoiding very fatty food, and staying well hydrated all help. If symptoms are severe or persistent, contact your prescriber before the next scheduled check-in, that's what aftercare is for, and it isn't a question worth sitting on.

A smaller number of people experience more serious reactions. Severe stomach pain that radiates towards the back, with or without vomiting, should be assessed urgently: this can be a sign of acute pancreatitis, a known but infrequent risk with GLP-1 medicines that the MHRA has specifically highlighted. Signs of a serious allergic reaction (swelling, difficulty breathing, a sudden rash) need emergency care. Yellow Card allows patients and carers to report any suspected reaction at yellowcard.mhra.gov.uk, and doing so helps the regulators monitor safety across the population.

Step 4: what comes next, and how private treatment works at this stage

After approximately four weeks at 1mg, the standard pathway moves to 1.7mg and then to the 2.4mg maintenance dose, though that progression always depends on how you are tolerating the current step. A prescriber may recommend staying at 1mg for longer if there are good clinical reasons. The schedule is a guide, not a guarantee. If you are reading this page while weighing up how to access treatment, the weight-loss treatment overview gives a clear picture of which medicines are licensed in the UK and what private treatment involves.

For people using a regulated online pharmacy, each dose step is typically reviewed before a new pen is supplied. At nume, a GPhC-registered Independent Prescriber personally reviews every repeat, and any dose increase requires evidence that the current step has been tolerated. There are no auto-renewals and no subscriptions, the clinical review happens each time. The cost of Wegovy through private pharmacies is a reasonable thing to look into at this stage, since private treatment at every dose level carries a price that reflects the clinical oversight included. Our clinical team page explains how that oversight is structured.

If you have specific questions about your own treatment or suitability, the free consultation is the right place to start. A prescriber can assess your full picture, not just the dose question, but everything relevant to whether semaglutide is the right choice for you.